Formulation and characterisation of PLGA microspheres as vaccine adjuvants

Immunomic Discovery of Adjuvants and Candidate Subunit Vaccines

Volumn , Issue , 2013, Pages 263-289

  Kirby, Daniel J ^a   Kaur, Randip ^a   Perrie, Yvonne ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84988228765     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-5070-2_13     Document Type: Chapter

References (158)

1. Agger E, Andersen P (2001) Tuberculosis subunit vaccine development: on the role of interferon-gamma. Vaccine 19:2298-2302
2. Aldous B, Auffret A, Franks F (1995) The crystallisation of hydrates from amorphous carbohydrates. Cryo Letters 16:181-186
3. Allemann E, Gurny R, Doelker E (1992) Preparation of aqueous polymeric nanodispersions by a reversible salting-out process: influence of process parameters on particle size. Int J Pharm 87:247-253
4. Allison A, Gregoriadis G (1974) Liposomes as immunological adjuvants. Nature 252:252
5. Allison S, Molina M, Anchordoquy T (2000) Stabilisation of lipid DNA complexes during the freezing step of the lyophilization process: the particle isolation hypothesis. Biochim Biophys Acta 1468:127-138
6. Anchordoquy T, Allison S, Molina M, Girouard L, Carson T (2001) Physical stabilization of DNA-based therapeutics. Drug Discov Today 6:463-470
7. Arshady R (1991) Preparation of biodegradable microspheres and microcapsules: 2. Polyactides and related polyesters. J Control Release 17:1-21
8. Audran R, Peter K, Dannull J, Men Y, Scandella E, Groettrup M, Gander B, Corradin G (2003) Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-I presentation by dendritic cells and macrophages in vitro. Vaccine 21:1250-1255
9. Bendix D (1998) Chemical synthesis of polylactide and its copolymers for medical applications. Polym Degrad Stabil 59:125-135
10. Benoit M, Baras B, Gillard J (1999) Preparation and characterization of protein-loaded poly (epsilon-caprolactone) microparticles for oral vaccine delivery. Int J Pharm 184:73-84
11. Boury F, Ivanova T, Panaiotov I, Proust J, Bois A, Richou J (1995) Dynamic properties of poly(DL-lactide) and polyvinyl alcohol monolayers at the air/water and dichloromethane/ water interfaces. J Colloid Interface Sci 169:380-392
12. Bozdag S, Dillen K, Vandervoort J, Ludwig A (2005) The effect of freeze-drying with different cryoprotectants and gamma-irradiation sterilization on the characteristics of ciprofloxacin HCl-loaded poly(D, L-lactide-glycolide) nanoparticles. J Pharm Pharmacol 57:699-707
13. Bramwell V, Perrie Y (2005) Particulate delivery systems for vaccines. Crit Rev Ther Drug Carrier Syst 22:151-214
14. Briones M, Singh M, Ugozzoli M, Kazzaz J, Klakamp S, Ott G, O'Hagan D (2001) The preparation, characterization, and evaluation of cationic microparticles for DNA vaccine delivery. Pharm Res 18:709-712
15. Brunner R, Wallmann J, Szalai K, Karagiannis P, Kopp T, Scheiner O, Jensen-Jarolim E, Pali-Scholl I (2007) The impact of aluminium in acid-suppressing drugs on the immune response of BALB/c mice. Clin Exp Allergy 37:1566-1573
16. Burns RJ, Vitale K, Sanders L (1990) Nafarelin controlled release injectable: theoretical clinical plasma profiles from multiple dosing and from mixtures of microspheres containing 2 per cent, 4 per cent and 7 per cent nafarelin. J Microencapsul 7:397-413
17. Capan Y, Woo B, Gebrekidan S, Ahmed S, DeLuca P (1999) Influence of formulation parameters on the characteristics of poly(D, L-lactide-co-glycolide) microspheres containing poly(L-lysine) complexed plasmid DNA. J Control Release 60:279-286
18. Carmona-Ribeiro A, Ortis F, Schumacher R, Armelin M (1997) Interactions between cationic vesicles and cultured mammalian cells. Langmuir 13:2215-2218
19. Chacon M, Molpeceres J, Berges L, Guzman M, Aberturas M (1999) Stability and freezedrying of cyclosporine loaded poly(D, L lactide-glycolide) carriers. Eur J Pharm Sci 8:99-107
20. Choi S, Kwon H, Kim W, Kim J (2002) Thermodynamic parameters on poly(d, l-lactide-coglycolide) particle size in emulsification-diffusion process. Colloids Surf A Physicochem Eng Asp 201:283-289
21. Chong C, Cao M, Wong W, Fischer K, Addison W, Kwon G, Tyrrell D, Samuel J (2005) Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery. J Control Release 102:85-99
22. Christensen D, Foged C, Rosenkrands I, Nielsen H, Andersen P, Agger E (2007) Trehalose preserves DDA/TDB liposomes and their adjuvant effect during freeze-drying. Biochim Biophys Acta 1768:2120-2129
23. Chung T, Wu S, Yao M, Lu C, Lin Y, Hung Y, Mou C, Chen Y, Huang D (2007) The effect of surface charge on the uptake and biological function of mesoporous silica nanoparticles in 3T3-L1 cells and human mesenchymal stem cells. Biomaterials 28:2959-2966
24. Cohen S, Chen L, Apte R (1995) Controlled release of peptides and proteins from biodegradable polyester microspheres: an approach for treating infectious diseases and malignancies. React Polym 25:177-187
25. Conway A, Madrigal-Estebas L, McClean S, Brayden D, Mills K (2001) Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles: effect of formulation and route of immunization on induction of Th1 and Th2 cells. Vaccine 19:1940-1950
26. Cooper A, Dalton D, Stewart T, Griffin J, Russell D, Orme I (1993) Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 178:2243-2247
27. Copland M, Rades T, Davies N (2000) Hydration of lipid films with an aqueous solution of Quil A: a simple method for the preparation of immune-stimulating complexes. Int J Pharm 196:135-139
28. Crowe J, Crowe L (1988) Factors affecting the stability of dry liposomes. Biochim Biophys Acta 939:327-334
29. Crowe L, Reid D, Crowe J (1996) Is trehalose special for preserving dry biomaterials? Biophys J 71:2087-2093
30. Davidsen J, Rosenkrands I, Christensen D, Vangala A, Kirby D, Perrie Y, Agger E, Andersen P (2005) Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,60-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses. Biochim Biophys Acta 1718:22-31
31. de Chasteigner S, Cavé G, Fessi H, Devissaguet J-P, Puisieux F (1998) Freeze-drying of itraconazole-loaded nanosphere suspension: a feasibility study. Drug Dev Res 38:116-124
32. Demana P, Davies N, Hook S, Rades T (2005) Quil A-lipid powder formulations releasing ISCOMs and related colloidal structures upon hydration. J Control Release 103:45-59
33. Demento S, Eisenbarth S, Foellmer H, Platt C, Caplan M, Saltzman M, Mellman I, Ledizet M, Fikrig E, Flavell R, Fahmy T (2009) Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy. Vaccine 27:3013-3021
34. Denis-Mize K, Dupuis M, Singh M, Woo C, Ugozzoli M, O'Hagan D, Donnelly JI, Ott G, McDonald D (2003) Mechanisms of increased immunogenicity for DNA-based vaccines adsorbed onto cationic microparticles. Cell Immunol 225:12-20
35. Diwan M, Tafaghodi M, Samuel J (2002) Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres. J Control Release 85:247-262
36. Dodane V, Vilivalam V (1998) Pharmaceutical applications of chitosan. Pharm Sci Technol Today 1:246-253
37. Domb A, Kumar N, Sheskin T, Bentolila A, Slager J, Teomim D (2002) Biodegradable polymers as drug carrier systems. In: Dumitriu S (ed) Polymeric biomaterials. Marcel Dekker, New York, pp 91-122
38. Duncan G, Jess T, Mohamed F, Price N, Kelly S, van der Walle C (2005) The influence of protein solubilisation, conformation and size on the burst release from poly(lactide-co-glycolide) microspheres. J Control Release 110:34-48
39. Eldridge J, Staas J, Meulbroek J, Tice T, Gilley R (1991) Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect Immun 59: 2978-2986
40. Esposito E, Sebben S, Cortesi R, Menegatti E, Nastruzzi C (1999) Preparation and characterization of cationic microspheres for gene delivery. Int J Pharm 189:29-41
41. Fattal E, Pecquet S, Couvreur P, Andremont A (2002) Biodegradable microparticles for the mucosal delivery of antibacterial and dietary antigens. Int J Pharm 242:15-24
42. Fearon K, Marshall JD, Abbate C, Subramanian S, Yee P, Gregorio J, Teshima G, Ott G, Tuck S, Van Nest G (2003) A minimal human immunostimulatory CpG motif that potently induces IFN-gamma and IFN-alpha production. Eur J Immunol 33:2114-2159
43. Feng L, Rong X, Xing Q, Zhou J, Maitani Y, Wang S, Jiang Y, Nagai T (2006) Pharmaceutical and immunological evaluation of a single-dose hepatitis B vaccine using PLGA microspheres. J Control Release 112:35-42
44. Fessi H, Puisieux F, Devissaguet J, Ammoury N, Benita S (1989) Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int J Pharm 55:1-4
45. Flynn J, Chan J, Triebold K, Dalton D, Stewart T, Bloom B (1993) An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 178:2249-2254
46. Freytag L, Clements J (2005) Mucosal adjuvants. Vaccine 23:1804-1813
47. Furr B, Hutchinson F (1985) Biodegradable sustained release formulation of the LH-RH analogue 'Zoladex' for the treatment of hormone-responsive tumours. Prog Clin Biol Res 185:143-153
48. Furukawa T, Matsusue Y, Yasunaga T, Shikinami Y, Okuno M, Nakamura T (2000) Biodegradation behavior of ultra-high-strength hydroxyapatite/poly (-lactide) composite rods for internal fixation of bone fractures. Biomaterials 21:889-898
49. Gall D (1966) The adjuvant activity of aliphatic nitrogenous bases. Immunology 11:369-386
50. Gheorghiu M, Lagranderie M, Balazuc A (1996) Stabilisation of BCG vaccines. Dev Biol Stand 87:251-261
51. Gopferich A (1996) Mechanisms of polymer degradation and erosion. Biomaterials 17:103-114
52. Hamdy S, Molavi O, Ma Z, Haddadi A, Alshamsan A, Gobti Z, Elhasi S, Samuel J, Lavasanifar A (2008) Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity. Vaccine 26:5046-5047
53. Hanafusa S, Matsusue Y, Yasunaga T, Yamamuro T, Oka M, Shikinami Y, Ikada Y (1995) Biodegradable plate fixation of rabbit femoral shaft osteotomies. A comparative study. Clin Orthop Relat Res 315:262-271
54. Harish Prashanth K, Tharanathan R (2007) Chitin/chitosan: modifications and their unlimited application potential an overview. Trends Food Sci Technol 18:117-131
55. Heath T, Lopez N, Papahadjopoulos D (1985) The effects of liposome size and surface charge on liposome-mediated delivery of methotrexate-[gamma]-aspartate to cells in vitro. Biochim Biophys Acta 820:74-84
56. Henriksen-Lacey M, Bramwell V, Christensen D, Agger E, Andersen P, Perrie Y (2010) Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen. J Control Release 142:180-186
57. Hornung V, Bauernfeind F, Halle A, Samstad E, Kono H, Rock K, Fitzgerald K, Latz E (2008) Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 9:847-856
58. Huang M, Khor E, Lim L (2004) Uptake and cytotoxicity of chitosan molecules and nanoparticles: effects of molecular weight and degree of deacetylation. Pharm Res 21:344-353
59. Igartua M, Hernandez R, Esquisabel A, Gascon A, Calvo M, Pedraz J (1998) Enhanced immune response after subcutaneous and oral immunization with biodegradable PLGA microspheres. J Control Release 56:63-73
60. Ishikawa E, Ishikawa T, Morita Y, Toyonaga K, Yamada H, Takeuchi O, Kinoshita T, Akira S, Yoshikai Y, Yamasaki S (2009) Direct recognition of the mycobacterial glycolipid, trehalose dimycolate, by C-type lectin Mincle. J Exp Med 206:2879-2888
61. Jabbal-Gill I, Lin W, Jenkins P, Watts P, Jimenez M, Illum L, Davis S, Wood J, Major D, Minor P (1999) Potential of polymeric lamellar substrate particles (PLSP) as adjuvants for vaccines. Vaccine 18:238-250
62. Jain R (2000) The manufacturing techniques of various drug loaded biodegradable poly (lactide-co-glycolide) (PLGA) devices. Biomaterials 21:2475-2490
63. Jalil R, Nixon J (1990) Biodegradable poly (lactic acid) and poly (lactide-coglycolide) microcapsules: problems associated with preparative techniques and release properties. J Microencapsul 7:297-325
64. Jamshidi K, Hyon S, Ikada Y (1988) Thermal characterization of polylactides. Polymer 29:2229-2234
65. Janeway CJ (1989) Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 54:1-13
66. Jiang W, Gupta R, Deshpande M, Schwendeman S (2005) Biodegradable poly(lactic-coglycolic acid) microparticles for injectable delivery of vaccine antigens. Adv Drug Deliv Rev 57:391-410
67. Jilek S, Merkle H, Walter E (2005) DNA-loaded biodegradable microparticles as vaccine delivery systems and their interaction with dendritic cells. Adv Drug Deliv Rev 57:377-390
68. Johansen P, Moon L, Tamber H, Merkle H, Gander B, Sesardic D (1999) Immunogenicity of single-dose diphtheria vaccines based on PLA/PLGA microspheres in guinea pigs. Vaccine 18:209-215
69. Jung T, Koneberg R, Hungerer K, Kissel T (2002) Tetanus toxoid microspheres consisting of biodegradable poly(lactide-co-glycolide)- and ABA-triblock-copolymers: immune response in mice. Int J Pharm 234:75-90
70. Khor E, Lim L (2003) Implantable applications of chitin and chitosan. Biomaterials 24:2339-2349
71. Kim H, Chung H, Park T (2006) Biodegradable polymeric microspheres with open/closed pores for sustained release of human growth hormone. J Control Release 112:167-174
72. Kirby C, Gregoriadis G (1984) Preparation of liposomes containing factor VIII for oral treatment of haemophilia. J Microencapsul 1:33-45
73. Kirby D, Rosenkrands I, Agger E, Andersen P, Coombes A, Perrie Y (2008) PLGA microspheres for the delivery of a novel subunit TB vaccine. J Drug Target 16:282-293
74. Kirby D, Rosenkrands I, Agger E, Andersen P, Coombes A, Perrie Y (2008) Liposomes act as stronger subunit vaccine adjuvants when compared to microspheres. J Drug Target 16:543-554
75. Kissel T, Koneberg R (1996) Injectable biodegradable microspheres for vaccine delivery. In: Cohen S, Bernstein H (eds) Microparticulate systems for the delivery of proteins and vaccines. Marcel Dekker, New York, pp 51-88
76. Konan Y, Gurny R, Allemann E (2002) Preparation and characterization of sterile and freezedried sub-200 nm nanoparticles. Int J Pharm 233:239-252
77. Koster K, Leopold A (1988) Sugars and desiccation tolerance in seeds. Plant Physiol 88:829-832
78. Langer R, Folkman J (1976) Polymers for the sustained release of proteins and other macromolecules. Nature 263:797-800
79. Lemoine D, Francois C, Kedzierewicz F, Preat V, Hoffman M, Maincent P (1996) Stability study of nanoparticles of poly(epsilon-caprolactone), poly(D, L-lactide) and poly (D, L-lactide-co-glycolide). Biomaterials 17:2191-2197
80. Levine H, Slade L (1988) Principles of 'cryostabilization' technology from structure/property relationships of carbohydrate/water systems-a review. Cryo-Lett 9:21-63
81. Lewis D (1990) Controlled release of bioactive agents from lactide/glycolide polymers. In: Chasin M, Langer R (eds) Biodegradable polymers as drug delivery systems. Marcel Dekker, New York, pp 1-41
82. Li B, Li S, Tan Y, Stolz D, Watkins S, Block L, Huang L (2000) Lyophilization of cationic lipid-protamine-DNA (LPD) complexes. J Pharm Sci 89:355-364
83. Linghua Z, Xingshan T, Fengzhen Z (2008) In vivo oral administration effects of various oligodeoxynucleotides containing synthetic immunostimulatory motifs in the immune response to pseudorabies attenuated virus vaccine in newborn piglets. Vaccine 26:224-233
84. Lloyd J (2000) Technologies for vaccine delivery in the 21st century. Department of Vaccines and Biologicals, World Health Organisation, Geneva, Switzerland
85. Luzardo-Alvarez A, Blarer N, Peter K, Romero J, Reymond C, Corradin G, Gander B (2005) Biodegradable microspheres alone do not stimulate murine macrophages in vitro, but prolong antigen presentation by macrophages in vitro and stimulate a solid immune response in mice. J Control Release 109:62-76
86. Mandal B, Kempf M, Merkle H, Walter E (2004) Immobilisation of GM-CSF onto particulate vaccine carrier systems. Int J Pharm 269:259-265
87. Manning M, Patel K, Borchardt R (1989) Stability of protein pharmaceuticals. Pharm Res 6:903-918
88. McCluskie M, Weeratna R, Krieg A, Davis H (2000) CpG DNA is an effective oral adjuvant to protein antigens in mice. Vaccine 19:950-957
89. Miyajima K, Tomita K, Nakagaki M (1986) Effect of saccharides on the freezing and thawing of liposome dispersion. Chem Pharm Bull 34:2689-2697
90. Mohammed A, Bramwell V, Coombes A, Perrie Y (2006) Lyophilisation and sterilisation of liposomal vaccines to produce stable and sterile products. Methods 40:30-38
91. Mohammed A, Coombes A, Perrie Y (2007) Amino acids as cryoprotectants for liposomal delivery systems. Eur J Pharm Sci 30:406-413
92. Mollenkopf H, Dietrich G, Fensterle J, Grode L, Diehl K, Knapp B, Singh M, O'Hagan D, Ulmer J, Kaufmann S (2004) Enhanced protective efficacy of a tuberculosis DNA vaccine by adsorption onto cationic PLG microparticles. Vaccine 22:2690-2695
93. Mori T, Okumura M, Matsuura M, Ueno K, Tokura S, Okamoto Y, Minami S, Fujinaga T (1997) Effects of chitin and its derivatives on the proliferation and cytokine production of fibroblasts in vitro. Biomaterials 18:947-951
94. Morokata T, Ishikawaa J, Yamada T (2000) Antigen dose defines T helper 1 and T helper 2 responses in the lungs of C57BL/6 and BALB/c mice independently of splenic responses. Immunol Lett 72:119-126
95. Moschos S, Bramwell V, Somavarapu S, Alpar H (2004) Adjuvant synergy: the effects of nasal coadministration of adjuvants. Immunol Cell Biol 82:628-637
96. Mosmann T, Sad S (1996) The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 17:138-146
97. Myschik J, Lendemans D, McBurney W, Demana P, Hook S, Rades T (2006) On the preparation, microscopic investigation and application of ISCOMs. Micron 37:724-734
98. Nishimura K, Nishimura S, Seo H, Nishi N, Tokura S, Azuma I (1987) Effect of multiporous microspheres derived from chitin and partially deacetylated chitin on the activation of mouse peritoneal macrophages. Vaccine 5:136-140
99. Nykamp G, Carstensen U, Muller B (2002) Jet milling a new technique for microparticle preparation. Int J Pharm 242:79-86
100. Ogawa Y, Yamamoto M, Okada H, Yashiki T, Shimamoto T (1988) A new technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid or copoly(lactic/ glycolic) acid. Chem Pharm Bull 36:1095-1103
101. O'Hagan D, MacKichan M, Singh M (2001) Recent developments in adjuvants for vaccines against infectious diseases. Biomol Eng 18:69-85
102. O'Hagan D, Rahman D, McGee J, Jeffery H, Davies M, Williams P, Davis S, Challacombe S (1991) Biodegradable microparticles as controlled release antigen delivery systems. Immunology 73:239-242
103. O'Hagan D, Singh M, Dong C, Ugozzoli M, Berger K, Glazer E, Selby M, Wininger M, Ng P, Crawford K, Paliard X, Coates S, Houghton M (2004) Cationic microparticles are a potent delivery system for a HCV DNA vaccine. Vaccine 23:672-680
104. Olds G, Chedid L, Lederer E, Mahmoud A (1980) Induction of resistance to Schistosomamansoni by natural cord factor and synthetic lower homologs. J Infect Dis 141:473-478
105. Ozaki K, Hayashi M (1998) Effect of cycloinulohexaose with additives on the freeze-drying of liposome. Int J Pharm 160:219-227
106. Patel V, Patel M, Patel R (2005) Chitosan: a unique pharmaceutical excipient. Drug Deliv Technol 5:30-40
107. Peluso G, Petillo O, Ranieri M, Santin M, Ambrosic L, Calabro D, Avallone B, Balsamo G (1994) Chitosan-mediated stimulation of macrophage function. Biomaterials 15:1215-1220
108. Perrie Y, Kirby D, Bramwell V, Mohammed A (2007) Recent developments in particulatebased vaccines. Recent Pat Drug Deliv Formul 1:117-130
109. Perrin D, English J (1997) Polyglycolide and polylactide. In: Domb A, Kost J, Wiseman D (eds) Handbook of biodegradable polymers. Harwood Academic Publishers, Amsterdam, pp 3-28
110. Petaja T, Keranen H, Karppa T, Kawa A, Lantela S, Siitari-Mattila M, Levanen H, Tocklin T, Godeaux O, Lehtinen M, Dubin G (2009) Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years. J Adolesc Health 44:33-40
111. Peyre M, Fleck R, Hockley D, Gander B, Sesardic D (2004) In vivo uptake of an experimental microencapsulated diphtheria vaccine following sub-cutaneous immunisation. Vaccine 22:2430-2437
112. Pimm M, Baldwin R, Polonsky J, Lederer E (1979) Immunotherapy of an ascitic rat hepatoma with cord factor (trehalose-6, 60-dimycolate) and synthetic analogs. Int J Cancer 24:780-785
113. Playfair J, Bancroft G (2004) Infection and immunity, 2nd edn. Oxford University Press, Oxford
114. Preis I, Langer R (1979) A single-step immunization by sustained antigen release. J Immunol Methods 28:193-197
115. Quaglia F, De R, Granata E, Ungaro F, Fattal E, Immacolata La Rotonda M (2003) Feeding liquid, non-ionic surfactant and cyclodextrin affect the properties of insulin-loaded poly (lactide-co-glycolide) microspheres prepared by spray-drying. J Control Release 86:267-278
116. Rafati H, Coombes A, Adler J, Holland J, Davis S (1997) Protein-loaded poly(-lactide-coglycolide) microparticles for oral administration: formulation, structural and release characteristics. J Control Release 43:89-102
117. Ravi Kumar M, Bakowsky U, Lehr C (2004) Preparation and characterization of cationic PLGA nanospheres as DNA carriers. Biomaterials 25:1771-1777
118. Ren J, Hong H, Song J, Ren T (2005) Particle size and distribution of biodegradable poly-D, L-lactide-co-poly(ethylene glycol) block polymer nanoparticles prepared by nanoprecipitation. J Appl Poly Sci 98:1884-1890
119. Roman B, Irache J, Gomez S, Tsapis N, Gamazo C, Espuelas M (2008) Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology. Eur J Pharm Biopharm 70:98-108
120. Rosas J, Pedraz J, Hernandez R, Gascon A, Igartua M, Guzman F, Rodriguez R, Cortes J, Patarroyo M (2002) Remarkably high antibody levels and protection against P. falciparum malaria in Aotus monkeys after a single immunisation of SPf66 encapsulated in PLGA microspheres. Vaccine 20:1707-1710
121. Rosenkrands I, Agger E, Olsen A, Korsholm K, Andersen C, Jensen K, Andersen P (2005) Cationic liposomes containing mycobacterial lipids-a new powerful Th1 adjuvant system. Infect Immun 73:5817-5826
122. Roy D, Guillon X, Lescure F, Couvreur P, Bru N, Breton P (1997) On shelf stability of freezedried poly(methylidene malonate 2.1.2) nanoparticles. Int J Pharm 148:165-175
123. Saez A, Guzman M, Molpeceres J, Aberturas M (2000) Freeze-drying of polycaprolactone and poly(D, L-lactic-glycolic) nanoparticles induce minor particle size changes affecting the oral pharmacokinetics of loaded drugs. Eur J Pharm Biopharm 50:379-387
124. Sarti F, Perera G, Hintzen F, Kotti K, Karageorgiou V, Kammona O, Kiparissides C, Bernkop-Schnurch A (2011) In vivo evidence of oral vaccination with PLGA nanoparticles containing the immunostimulant monophosphoryl. Biomaterials 32:4052-4057
125. Sartia F, Pereraa G, Hintzena F, Kottib K, Karageorgioub V, Kammonab O, Kiparissidesb C, Bernkop-Schnurcha A (2011) In vivo evidence of oral vaccination with PLGA nanoparticles containing the immunostimulant monophosphoryl lipid A. Biomaterials 32:4052-4057
126. Schoenen H, Bodendorfer B, Hitchens K, Manzanero S, Werninghaus K, Nimmerjahn F, Agger E, Stenger S, Andersen P, Ruland J, Brown G, Wells C, Lang R (2010) Cutting edge: mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalose-dibehenate. J Immunol 184:2756-2760
127. Schondorf I, Banzhoff A, Nicolay U, Diaz-Mitoma F (2007) Overcoming the need for a cold chain with conjugated meningococcal Group C vaccine: a controlled, randomized, doubleblind study in toddlers on the safety and immunogenicity of Menjugate, stored at room temperature for 6 months. Vaccine 25:1175-1182
128. Seville P, Kellaway I, Birchall J (2002) Preparation of dry powder dispersions for non-viral gene delivery by freeze-drying and spray-drying. J Gene Med 4:428-437
129. Singh A, Kasinath B, Lewis E (1992) Interaction of polycations with cell-surface negative charges of epithelial cells. Biochim Biophys Acta 1120:337-342
130. Sinha V, Trehan A (2003) Biodegradable microspheres for protein delivery. J Control Release 90:261-280
131. Smith Korsholm K, Agger E, Foged C, Christensen D, Dietrich J, Andersen C, Geisler C, Andersen P (2007) The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes. Immunology 121:216-226
132. Storni T, Kundig T, Senti G, Johansen P (2005) Immunity in response to particulate antigendelivery systems. Adv Drug Deliv Rev 57:333-355
133. Strong P, Clark H, Reid K (2002) Intranasal application of chitin microparticles downregulates symptoms of allergic hypersensitivity to Dermatophagoides pteronyssinus and Aspergillus fumigatus in murine models of allergy. Clin Exp Allergy 32:1794-1800
134. Sun W, Leopold A, Crowe L, Crowe J (1996) Stability of dry liposomes in sugar glasses. Biophys J 70:1769-1776
135. Tabata Y, Ikada Y (1988) Effect of the size and surface charge of polymer microspheres on their phagocytosis by macrophage. Biomaterials 9:356-362
136. Tabata Y, Ikada Y (1988) Macrophage phagocytosis of biodegradable microspheres composed of L-lactic acid/glycolic acid homo- and copolymers. J Biomed Mater Res 22:837-858
137. Tamber H, Johansen P, Merkle H, Gander B (2005) Formulation aspects of biodegradable polymeric microspheres for antigen delivery. Adv Drug Deliv Rev 57:357-376
138. Tice T, Cowsar DB (1984) Biodegradable controlled-release parenteral systems. J Pharm Technol 8:26-31
139. Vangala A, Bramwell V, McNeil S, Christensen D, Agger E, Perrie Y (2007) Comparison of vesicle based antigen delivery systems for delivery of hepatitis B surface antigen. J Control Release 119:102-110
140. Vila A, Sanchez A, Tobio M, Calvo P, Alonso M (2002) Design of biodegradable particles for protein delivery. J Control Release 78:15-24
141. Vrancken M, Claeys D (1970) Method for encapsulating water and compounds in aqueous phase by extraction. US Patent 3523907
142. Werninghaus K, Babiak A, Groß O, Holscher C, Dietrich H, Agger E, Mages J, Mocsai A, Schoenen H, Finger K, Nimmerjahn F, Brown G, Kirschning C, Heit A, Andersen P, Wagner H, Ruland J, Lang R (2009) Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRg-Syk-Card9-dependent innate immune activation. J Exp Med 206:89-97
143. Wischke C, Borchert H, Zimmermann J, Siebenbrodt I, Lorenzen D (2006) Stable cationic microparticles for enhanced model antigen delivery to dendritic cells. J Control Release 114:359-368
144. Ahsan, F., Rivas, I.P., Khan, M.A., Torres Suarez, A.I. (2002) Targeting to macrophages: role of physicochemical properties of particulate carriers-liposomes and microspheres-on the phagocytosis by macrophages. J. Control Release, 79, 29-40
145. Alpar, H.O., Somavarapu, S., Atuah, K.N., Bramwell, V.W. (2005) Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Advanced Drug Delivery Reviews, 57, 411-430
146. Brunner, R., Jensen-Jarolim, E., Pali-Schöll, I. (2010) The ABC of clinical and experimental adjuvants-A brief overview. Immunology Letters, 128(1), 29-35
147. Brandt, L., Elhay, M., Rosenkrands, I., Lindblad, E.B., Andersen, P. (2000) ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect. Immun., 68, 791-795
148. Crowe, J.H., Leslie, S.B., Crowe, L.M. (1994a) Is vitrification sufficient to preserve liposomes during freeze-drying? Cryobiology, 31, 355-366
149. Davis, H.L., Weeratna, R., Waldschmidt, T.J., Tygrett, L., Schorr, J., Krieg, A.M. (1998) CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol., 160, 870-876
150. Hamdy, S., Haddadi, A., Somayaji, V., Ruan, D., Samuel, J. (2007) Pharmaceutical analysis of synthetic lipid A-based vaccine adjuvants in poly (d,l-lactic-co-glycolic acid) nanoparticle formulations. Journal of Pharmaceutical and Biomedical Analysis, 44(4), 914-92
151. Holten-Andersen, L., Doherty, T.M., Korsholm, K.S., Andersen, P. (2004) Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterialcord factor as an efficient adjuvant for tuberculosis subunit vaccines. Infect. Immun., 72, 1608-1617
152. Illum, L., Farraj, N.F., Davis, S.S. (1994) Chitosan as a Novel Nasal Delivery System for Peptide Drugs. Pharmaceutical Research, 11, 1186-1189
153. Klinguer, C., Beck, A., De-Lys, P., Bussat, M.C., Blaecke, A., Derouet, F., Bonnefoy, J.Y., Nguyen, T.N., Corvaia, N., Velin, D. (2001) Lipophilic quaternary ammonium salt acts as a mucosal adjuvant when co-administered by the nasal route with vaccine antigens. Vaccine, 19, 4236-4244
154. Lindblad, E.B., Elhay, M.J., Silva, R., Appelberg, R., Andersen, P. (1997) Adjuvant modulation of immune responses to tuberculosis subunit vaccines. Infect. Immun., 65, 623-629
155. McCluskie, M.J., Davis, H.L. (1998) CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J. Immunol., 161, 4463-4466
156. Singh, M., Ugozzoli, M., Briones, M., Kazzaz, J., Soenawan, E., O'Hagan, D.T. (2003) The effect of CTAB concentration in cationic PLG microparticles on DNA adsorption and in vivo performance. Pharm. Res., 20, 247-251
157. Snippe, H., de Reuver, M.J., Beunder, J.W., van der Meer, J.B., van Wichen, D.F., Willers, J. M. (1982) Delayed-type hypersensitivity in rabbits. Comparison of the adjuvants dimethyl dioctadecyl ammonium bromide and Freund's complete adjuvant. Int. Arch. Allergy Appl. Immunol., 67, 139-144
158. Ulrich, J.T., Myers, K.R. (1995) Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Pharm. Biotechnol., 6, 495-524